Endovia welcomes federal support to reschedule cannabis to Schedule III
The company views the federal government's policy shift as a significant evolution in cannabinoid regulation, which could remove legal barriers to research. Endovia plans to submit its CannEpil formulation and request an FDA pre-submission conference.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day